No significant clinical disorders detected. The metabolic improvements over 15 months are real and meaningful — insulin has collapsed, triglycerides are on a clean downward trend, and liver function is excellent. However, this panel reveals a critical cluster: an acute inflammatory spike strongly suggesting a likely infection at time of testing, a declining free testosterone now below range, and a supplement stack simultaneously creating B6 and selenium toxicity while leaving B1 critically deficient. These three issues are interconnected and all point to the same root cause: an unreviewed supplement protocol.
Three markers moved simultaneously: ESR jumped from 3 → 20 mm/hr (was comfortably low-normal for three consecutive panels), Lymphocyte % spiked from ~47% to 54.8% above its range of 15–49%, and urine appearance changed to Turbid for the first time across all panels. Urinary microalbumin also spiked from 5.5 → 13.27 µg/mL.
This cluster strongly suggests Jude had an active infection or acute inflammatory episode around the time of testing. Several borderline results this panel — neutrophil % (37.8%, just below range), MCHC (31.2), PDW (16.6) — are likely confounded. Recheck these in 4–6 weeks to confirm resolution before drawing structural conclusions.
Free testosterone trajectory across all panels: 5.33 → 9.35 → 8.06 → 5.41 pg/mL (range 8.70–25.10). It peaked briefly at 9.35 in Jun 2025 and has since reversed completely. Total testosterone at 351 ng/dL is in range and SHBG is normal at 20.4 — the issue is not binding. Something is actively suppressing free T conversion or upstream androgen synthesis.
Androstenedione — a direct testosterone precursor — is also declining: 90 → 98 → 117 → 67.3 ng/dL. This is a precursor pathway problem. The three most likely causes: chronically elevated B6 which directly interferes with androgen metabolism, excess selenium at 187.55 µg/L, and the active inflammatory state at time of testing. All three are addressable. At 35, this trajectory requires intervention now before it compounds further.
Vitamin B6 is at 48.57 ng/mL — more than double the upper range of 21.70. Every panel has shown escalation: 7.14 → 30.32 → 19.32 → 48.57. At sustained levels this high, peripheral neuropathy (tingling, numbness in hands and feet), photosensitivity, nausea, and motor coordination issues are established clinical risks. Critically, excess B6 directly suppresses androgen synthesis — this is likely the primary driver of the free testosterone decline.
Vitamin B2 is similarly over-range at 24.34 ng/mL (range 2.33–14.68) and also escalating. A high-dose B-complex or multiple overlapping supplement products is the almost certain cause. The entire B-complex protocol needs immediate suspension and rational reconstruction.
Selenium went from 94.13 (Oct 2025) to 187.55 µg/L in a single panel interval — nearly doubling and pushing well above the optimal range of 63–160. A new selenium supplement was almost certainly added since the last test. At these levels, insulin sensitivity is directly impaired (selenium excess is associated with increased T2D risk) and research specifically flags elevated prostate cancer mortality risk in males supplementing above 140 µg/day chronically.
Stop all selenium supplementation immediately. Audit every supplement and multivitamin product for selenium content. Levels should normalize within 60–90 days given selenium's biological half-life.
B1 is critically low at 0.58 ng/mL (range 2.70–10.12). The pattern across panels: 2.19 → 0.74 → 2.62 → 0.58 — it spikes briefly when actively supplemented and crashes again, never holding. Thiamin is foundational for cellular ATP production, neurological function, cardiac health, and immune response. Sustained low B1 drives fatigue, brain fog, muscle weakness, and impaired cardiovascular function.
The paradox is stark: B6 and B2 are massively over-supplemented while B1 stays critically deficient. The current B-complex product has a deeply imbalanced ratio. Switch to isolated thiamin HCl or TTFD (fat-soluble thiamin), dosed consistently — not dependent on a combined product where B6 and B2 dominate.
D3 at 27.53 ng/mL is an unsupplemented natural baseline — Jude has not been taking any Vitamin D3 prior to 08/04/2026. The trajectory from 10.61 → 20.05 → 28.63 → 27.53 represents natural D3 fluctuation driven by sunlight exposure, diet, and seasonal variation in Bangkok. This is actually a positive foundation — his baseline without supplementation is already in the insufficiency zone rather than severe deficiency, suggesting reasonable sun exposure.
The doctor prescribed DV 60K (60,000 IU cholecalciferol) and correctly advised against D3 injections — these create pharmacokinetic peaks and troughs, carry hypercalcemia risk, and are difficult to titrate safely. The oral weekly loading protocol starting now should push D3 above 50 ng/mL within 8–10 weeks. D3 optimization will directly support testicular testosterone synthesis and correlates with improvement in Apo A1 — making this one of the higher-leverage interventions in the current plan.
Apo A1 — the structural protein of HDL — is 103 mg/dL against an optimal range of 115–178. It has been consistently below range across all four tests: 100 → 105 → 110 → 103. Research positions low Apo A1 as an equally strong cardiovascular predictor as low HDL-C, and in several studies a stronger predictor of heart disease mortality than LDL-C or HDL-C. Combined with HS-CRP at 1.5 mg/L (above optimal of 1.0, though improving from 2.7) and homocysteine at 13 µmol/L (high-normal), the cardiovascular inflammation picture needs active, sustained intervention.
Lipase has returned above range: 68.1 → 41.5 → 46.6 → 63.5 U/L (range 7–60). Amylase is normal at 83.5. Without GI symptoms, mildly elevated lipase most often reflects dietary fat load, alcohol consumption, or gut irritation. The recurring pattern — elevated in Jan 2025 and again now after improvement — warrants dietary inquiry. If elevated a third consecutive time, a GI consult is warranted to rule out subclinical pancreatic irritation.
Antimony has been above range across every panel: 10.4 → 15.35 → 7.41 → 9.72 µg/L (range 0–6). It fluctuates but never clears — indicating a persistent, low-level environmental source rather than a one-off exposure. Most likely source: drinking water, cookware glazing, or occupational. A urine antimony test provides a more accurate and reliable measurement than blood; recommend this as the next step.
Every supplement Jude is currently taking has been reviewed and cross-referenced against his blood panel results. The audit identified the direct cause of the B6 toxicity, the B2 elevation, and provides a probable explanation for the B1 crash — all from the same two products taken simultaneously. Each product below is rated and detailed.
| Ingredient | Amount | % DV | Assessment |
|---|---|---|---|
| Thiamine (B1) as HCl | 100 mg | 8,333% | High dose but B1 blood level is 0.58 — likely not absorbing well in HCl form |
| Riboflavin (B2) | 75 mg | 5,769% | PRIMARY CAUSE of blood B2 at 24.34 ng/mL (over-range) |
| Niacin (B3) | 100 mg | 625% | Within tolerable range; blood B3 at 0.63 (normal) |
| Vitamin B6 as pyridoxine HCl + P5P | 100 mg | 5,882% | PRIMARY CAUSE of blood B6 at 48.57 ng/mL — toxic range, actively suppressing testosterone |
| Folate (L-5-MTHF) | 680 mcg | 170% | Active methylated form — appropriate, blood folate at 13.8 (good) |
| Vitamin B12 (methylcobalamin) | 300 mcg | 12,500% | Very high dose; blood B12 541 pg/mL (normal range, not toxic) |
| Biotin | 1,000 mcg | 3,333% | Contributes to total biotin load; interferes with TSH and other immunoassays at high doses |
| Pantothenic Acid (B5) | 500 mg | 10,000% | Extremely high dose; blood B5 at 100.19 (within range) |
| Calcium | 50 mg | 4% | Negligible contribution |
| Inositol | 100 mg | — | No DV established; generally safe |
| PABA | 50 mg | — | No DV established; generally safe at this dose |
This single product is the primary driver of two confirmed blood toxicities. The 100mg B6 dose — especially in the pyridoxine HCl form — is known to accumulate in tissues and impair androgen synthesis when sustained at high levels. At 48.57 ng/mL, Jude is well into the range where peripheral neuropathy becomes a real risk if continued. The 75mg B2 dose provides no therapeutic benefit at this level and is purely excessive. Neither dose is appropriate for a maintenance supplement in a healthy 35-year-old.
The 100mg B1 as thiamine HCl should theoretically resolve the B1 deficiency — but the competing high-dose B6 actively impairs thiamine transport across cell membranes. This explains why blood B1 remains critically low despite theoretically adequate B1 dosing. The form is also wrong: HCl form has poor bioavailability compared to TTFD (fat-soluble thiamine), which crosses the blood-brain barrier and is far more effective at raising intracellular levels.
Do not replace with another combined B-complex. Instead, use targeted individual B vitamins once blood levels normalize: Isolated thiamin as TTFD or benfotiamine 100–300mg/day (fat-soluble, far superior absorption) to resolve the B1 deficiency. After 90 days and once B6 clears, consider a low-dose maintenance B-complex with B6 not exceeding 10–25mg per serving. Continue the methylfolate and methylcobalamin from this product via other sources if needed — levels are currently healthy.
| Ingredient | Amount | % RDA | Assessment |
|---|---|---|---|
| Vitamin B1 (Thiamine) | 7.5 mg | 500% | Woefully insufficient to correct blood B1 of 0.58 ng/mL. Also in HCl form. |
| Vitamin B2 (Riboflavin) | 8.5 mg | 500% | Adds to B2 load from high-dose B-complex — compounding the over-range result |
| Vitamin B3 (Niacinamide) | 60 mg | 300% | Safe range; combined with other product still fine |
| Vitamin B5 (Pantothenic acid) | 20 mg | — | Fine; blood B5 normal |
| Vitamin B6 (Pyridoxine) | 10 mg | 500% | Adds to B6 load — contributing to the 48.57 ng/mL blood reading |
| Vitamin B12 (Cyanocobalamin) | 10 mcg | 167% | Lower form (cyano vs methyl) — redundant given the other B-complex |
| Folate | 200 mcg | 50% | Fine; blood folate normal at 13.8 |
| Biotin | 50 mcg | 17% | Minor contribution; not a concern at this dose |
| Choline Bitartrate | 50 mg | — | Useful but redundant here |
| Inositol / PABA | 50 mg each | — | Fine; no concerns |
This product is the second layer of the double-stacking problem. On its own, it would be an ordinary maintenance B-complex. But taken alongside the high-dose B-complex (Image 6), it becomes the additive that pushes B6 and B2 over the toxicity threshold. The 7.5mg B1 dose is also far too low to correct a severe deficiency — it has been providing false reassurance that B1 needs are being met when they are not.
Additionally, the B12 here is in cyanocobalamin form — the lowest bioavailability form. Given that the other product already provides 300mcg methylcobalamin, this product offers no meaningful additional benefit and only compounds the B6/B2 problem.
| Ingredient | Amount | Assessment |
|---|---|---|
| Biotin (Vitamin B7) | 10,000 mcg | Pharmacological dose — 333× the recommended daily intake of 30mcg. FDA has issued warnings about high-dose biotin interfering with laboratory immunoassay tests. |
At 10,000mcg, biotin causes clinically significant interference with streptavidin-biotin immunoassays — the technology used for TSH, free T4, free T3, troponin, vitamin D, and several other common blood tests. High biotin competes with the assay chemistry and can produce falsely low TSH (suggesting hyperthyroidism when thyroid function is actually normal) or falsely elevated results depending on the assay design. Jude's TSH of 3.67 may be real — or it may be partially suppressed by residual biotin from this product. The blood biotin result in Oct 2025 was 7.0 ng/mL (above normal range of 0.22–3.0), directly confirming active supplementation at that time. It is now 0.45, suggesting the bottle was recently finished or stopped.
The B-complex (Image 6) still contributes 1,000mcg biotin per serving — once that product also stops, biotin will clear within 1–2 weeks and TSH should be retested to confirm its true value.
Biotin at 10,000mcg is used clinically for rare biotin-dependent enzyme disorders and some neurological conditions. For general hair, nail, or skin health — the common reason people take it — doses of 1,000–5,000mcg are more than sufficient, and even those are pharmacological rather than physiological. If Jude has genuine reasons to supplement biotin (e.g. hair loss, nail brittleness), switch to a maximum of 2,500mcg standalone, taken at least 8 hours before any blood draw.
| Ingredient | Amount | Assessment |
|---|---|---|
| Cholecalciferol (D3) | 60,000 IU per capsule | Correct medical loading-dose format. Doctor prescribed. Oral weekly loading is the right protocol — injections correctly avoided due to hypercalcemia risk and poor titratability. Supplementation started 08/04/2026. |
Important update: Jude has not been supplementing Vitamin D3 prior to this panel. The DV 60K was prescribed and started only on 08/04/2026 — the day before this report was reviewed. This means the blood level of 27.53 ng/mL is a genuine unsupplemented baseline, not a failed supplementation result. The trajectory from 10.61 → 20.05 → 28.63 → 27.53 reflects natural improvement through sunlight, diet, and lifestyle in Bangkok — a positive sign that his body responds well to D3 synthesis pathways.
The doctor correctly advised against D3 injections (megadose IM format) — these create extreme peaks and troughs in serum D3, can cause hypercalcemia in susceptible individuals, and are pharmacologically difficult to titrate. The oral DV 60K weekly loading protocol is the right clinical approach. Starting now from a baseline of 27.53 ng/mL, the weekly loading protocol should achieve optimal levels of 50–80 ng/mL within 8–10 weeks.
To achieve and sustain D3 above 50 ng/mL, the protocol is: (A) weekly DV 60K for 8 weeks as loading, then (B) switch to daily 5,000 IU soft gel for sustainable maintenance. Daily format is far easier to titrate and avoids the pharmacokinetic peaks of the weekly mega-dose format long-term.
Phase 1 — Loading (8 weeks): One DV 60K capsule per week, taken with a fat-containing meal (olive oil, avocado, nuts — fat is required for D3 absorption). Always take with K2 MK-7 (upgrade the dose — see below). Phase 2 — Maintenance: After 8 weeks switch to a daily 5,000 IU soft gel format for consistent levels without peaks and troughs. Retest D3 at 90 days. Target: 50–80 ng/mL. Do not exceed 100 ng/mL. The K2 MK-7 at 55mcg in the current stack must be upgraded to 100–200mcg MK-7 — this is non-negotiable when running a D3 loading protocol at this dose level.
| Ingredient | Amount | Assessment |
|---|---|---|
| Vitamin K2 MK-7 (natural) | 55 mcg/serving | Correct form (MK-7 preferred over MK-4 for superior half-life) but sub-therapeutic dose when paired with high-dose D3 supplementation. Blood K at 0.14 ng/mL is within range but at the very low end (0.13–1.50). |
Vitamin K2 MK-7 works synergistically with D3 by activating matrix GLA protein (MGP) and osteocalcin — the proteins that direct calcium to bone and away from arterial walls. When D3 supplementation is increased significantly (which it must be), the demand for K2 to activate D3-dependent calcium transport also increases. At 55mcg K2 MK-7 paired with high-dose D3 loading, there is insufficient K2 to fully activate MGP. This means supplemental calcium from D3 activity could potentially deposit in soft tissues rather than bone — a small but real risk at inadequate K2 levels. The standard recommendation when taking 5,000+ IU D3 daily is 100–200mcg MK-7. This product offers the correct form but at half the required dose.
Note: Blood vitamin K at 0.14 ng/mL (range 0.13–1.50) is at the floor of the reference range — essentially the minimum acceptable. This low level is partly why the cardiovascular markers (Apo A1, arterial calcification risk) remain suboptimal. K2 status and D3 status are closely linked.
Replace the 55mcg product with a 180–200mcg MK-7 product, or double the current dose (2 capsules = 110mcg) as an interim step. Take with the D3 and a fat-containing meal. MK-7 has a half-life of approximately 72 hours, making once-daily dosing effective. Brands offering 100–200mcg MK-7 per capsule: Life Extension, Jarrow Formulas, Thorne Research, or local equivalents available in Bangkok/India.
| Ingredient | Amount | Assessment |
|---|---|---|
| Folic Acid | 500 mcg | Standard folic acid form (not methylfolate). Blood folate is currently at 13.8 ng/mL — within the good range of 5.41–20.00. This product is labelled for pregnancy/neural tube defect prevention. |
Blood folate is currently in a healthy range at 13.8 ng/mL, up from 3.7 → 4.7 → 12.4 → 13.8 across panels — the folate supplementation is working. However, this product is designed for pre-pregnancy supplementation to prevent neural tube defects, which is not Jude's clinical indication. The standard folic acid form in this product requires conversion to active methylfolate via the MTHFR enzyme. Approximately 40% of the population carries MTHFR variants that reduce this conversion efficiency.
Once the B-complex products are stopped, folate supplementation from this product alone should continue — but consider switching to methylfolate (L-5-MTHF) 400–800mcg as it bypasses MTHFR entirely. If Jude has confirmed MTHFR status, this switch is more important. The high-dose B-complex (Image 6) already contains 680mcg L-5-MTHF — once that stops, this product becomes the sole folate source. Continue it for now; reassess at next panel when B-complex changes have been made.
For homocysteine reduction (currently 13 µmol/L — high-normal), adequate folate combined with B12 and B6 at physiological (not toxic) doses is the correct approach.
Blackmores Omega Triple Daily provides 900mg Omega-3 per capsule — a therapeutically meaningful dose. The label indicates DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) concentrate, which at 900mg total omega-3 per capsule puts a 2-capsule daily dose at approximately 1,800mg Omega-3. For Apo A1 elevation, HS-CRP reduction, and cardiovascular protection, the evidence-based therapeutic dose is 2–3g EPA+DHA daily. Two capsules of this product approaches the lower threshold.
Omega-3 is one of the few supplements with strong evidence for raising Apo A1 and lowering both triglycerides and HS-CRP — all three of which are flagged in this panel. Triglycerides have improved dramatically across panels (101 → 61 mg/dL) and this product is a likely contributor. Apo A1 and HS-CRP still need work, and maintaining or increasing Omega-3 dose to 3g/day would support both.
Confirm whether Jude is taking 1 or 2 capsules daily. For maximum cardiovascular and anti-inflammatory benefit, 2 capsules (1,800mg Omega-3) minimum is recommended. Taking with the largest meal of the day reduces the chance of fish burps and improves absorption. Store in fridge after opening to prevent oxidation. This is a premium product at a therapeutic dose — no change needed.
This is not a BCM-95 formulation (that uses 97% curcuminoids + essential oil complex) but a 95% curcuminoids + ginger root combination. The AIWO report recommended "Curcumin Rich" (BCM-95 at 480mg + piperine 20mg) — this Carbamide Forte product at 1,500mg 95% curcuminoids + ginger is a different but also valid approach. Ginger root extract has independent anti-inflammatory activity and complements curcumin's COX-2 inhibition. Piperine (black pepper extract) is absent from this product — curcumin bioavailability without piperine is very low. Adding a piperine product or switching to BCM-95 formulation would improve efficacy by 20×.
That said, at 1,500mg 95% curcuminoids even with lower bioavailability, there is likely meaningful absorption. HS-CRP has improved from 2.7 → 1.5 over the period this product may have been in the stack — though diet and lifestyle changes also contributed. Continue but consider adding 10–20mg piperine with each dose or switching to BCM-95 format.
This is an excellent, well-formulated product. Vitamin C at 1,000mg supports collagen synthesis, iron absorption, immune function, and has independent evidence for HS-CRP reduction. The Amla extract (Indian gooseberry) provides additional polyphenols and tannins that extend the antioxidant activity of ascorbic acid — it is a superior format to plain ascorbic acid tablets. The zinc addition is particularly relevant for Jude: serum zinc at 108.45 µg/dL has been declining across panels (167.25 → 153.6 → 108.45) and zinc is a critical co-factor in testosterone synthesis and immune function.
Note: This product overlaps with the NAC product (Image 10) which also contains Vitamin C. Total Vitamin C intake may exceed 1,500mg/day. Not harmful — the upper tolerable intake is 2,000mg — but consolidating to one Vitamin C source after reviewing the NAC product label is worth considering.
NAC (N-Acetyl Cysteine) at 600mg is a clinically validated dose with multiple relevant benefits for Jude's current profile. It is a glutathione precursor — the body's master antioxidant — and directly supports liver detoxification pathways, which is relevant given the supplement toxicity load Jude has been carrying. NAC has evidence for reducing oxidative stress markers, supporting mucosal immunity, and assisting with the detoxification of heavy metals including antimony. Given Jude's persistently elevated antimony levels across all panels, NAC may be providing partial mitigation benefit.
The additional Vitamin C in this product creates overlap with Image 2 — but the combined total is unlikely to exceed the 2,000mg tolerable upper intake. Once the B-complex products are stopped and the stack is rationalized, this minor overlap can be reassessed.
Blood B1 at 0.58 ng/mL is critically low across all four panels despite both B-complex products containing B1. The problem is two-fold: both products use thiamine HCl, the cheapest but least bioavailable form, which has poor intestinal absorption, especially when competing with high-dose B6 that impairs thiamine transport. Additionally, once thiamine HCl is absorbed, it requires phosphorylation to the active form (TPP) which is impaired when B6 is at toxic levels.
TTFD (thiamine tetrahydrofurfuryl disulfide) and benfotiamine are fat-soluble thiamine derivatives that bypass the transporter competition and achieve much higher intracellular levels. TTFD crosses the blood-brain barrier and is the preferred form for neurological B1 deficiency. Benfotiamine is preferred for peripheral neuropathy and metabolic support. Either is dramatically superior to HCl form for correction of established deficiency.
Start only after stopping the B-complex products so that B6 begins to clear. Adding fat-soluble thiamine while B6 remains at 48.57 ng/mL will still face some competitive interference. Within 4–6 weeks of B-complex cessation, B6 should drop significantly and thiamine supplementation will be far more effective.
Available brands: Thiamax (TTFD, 100mg capsules — considered the gold standard), Benfotiamine Inc. (benfotiamine 150mg), Life Extension Mega Benfotiamine (250mg). All available via iHerb or Amazon. Protocol: start at 100mg/day with food, increase to 200–300mg/day after 2 weeks if tolerated. Take with magnesium (see below) as magnesium is required for thiamine activation — currently absent from the stack.
Magnesium is not currently in the stack despite being involved in over 300 enzymatic reactions. Most critically for Jude: magnesium is required for thiamine (B1) activation — without adequate magnesium, supplemented B1 cannot be converted to the active coenzyme form (TPP). This is a primary reason B1 stays low despite supplementation. Magnesium is also required for Vitamin D3 activation (conversion to the active 1,25-dihydroxy form in the kidneys), which helps explain why D3 levels are stalling despite supplementation.
Blood magnesium is 2.04 mg/dL — within range (1.5–2.5) but this reflects serum magnesium, which is a poor indicator of intracellular magnesium status. Approximately 99% of magnesium is intracellular; serum levels can appear normal while tissue depletion is significant. Given the B1 activation failure and D3 stalling, functional magnesium insufficiency is a real possibility.
Additionally, magnesium has strong evidence for free testosterone support (acts as a co-factor in testosterone synthesis), HS-CRP reduction, and sleep quality improvement — all directly relevant to Jude's current panel findings.
Use magnesium glycinate (best tolerated, good bioavailability, calming effect) or magnesium threonate (superior blood-brain barrier penetration, brain/cognition focus). Avoid magnesium oxide (poorly absorbed, causes GI distress) and magnesium citrate (laxative effect at higher doses). Dose: 300–400mg elemental magnesium daily, taken with the evening meal or before bed (supports sleep quality). Available: Doctor's Best Magnesium Glycinate, Thorne Magnesium Bisglycinate, Magtein (threonate form). Available on iHerb.
| Supplement | Dose | Timing | Purpose / Target Marker | Status |
|---|---|---|---|---|
| Thiamin TTFD or Benfotiamine | 100–300 mg | With breakfast | Correct B1 deficiency (0.58 → target 2.70+) | ➕ Add |
| Magnesium Glycinate | 300–400 mg | Evening meal / bedtime | Activate B1 + D3, testosterone support, sleep, HS-CRP | ➕ Add |
| DV 60K (Vitamin D3 60,000 IU) · started 08/04 | 60,000 IU × weekly | With fatty meal, weekly × 8 weeks then switch to 5,000 IU daily | Load D3 from 27.53 baseline to 50–80 ng/mL; testosterone + Apo A1 | ✅ Keep — weekly |
| Vitamin K2 MK-7 (upgrade) | 180–200 mcg | With D3 dose + fat | D3 synergy, calcium direction, vascular health, Apo A1 | 🟠 Upgrade dose |
| Blackmores Omega Triple Daily | 2 capsules (1,800 mg) | With main meal | Apo A1 ↑, TG ↓, HS-CRP ↓ | ✅ Keep |
| Curcumin 95% + Ginger 1500 mg | 1,500 mg + piperine 20 mg | Post breakfast + post dinner | HS-CRP ↓ (add piperine for 20× bioavailability) | ✅ Keep + piperine |
| Vitamin C 1,000 mg + Amla + Zinc | 1,000 mg C + Zinc | With meal | Apo A1, immunity, zinc for testosterone pathway | ✅ Keep |
| NAC 600 mg + Vitamin C | 600 mg NAC | With meal | Glutathione support, liver, antimony detox pathway | ✅ Keep |
| Blackmores Bio Folic | 500 mcg | With meal | Maintain folate (13.8), homocysteine reduction | Review at 90 days |
| High-dose B-Complex (Image 6) | STOP | Immediately | B6 toxicity, B2 toxicity, biotin interference — causing free T crash | 🛑 Stop |
| Blackmores B-Complex Thai (Image 9) | STOP | Immediately | Double-stacking B6 + B2 — additive to toxicity | 🛑 Stop |
| Biotin 10,000 mcg Standalone | STOP | Immediately | Immunoassay interference; TSH result may be artifactual | 🛑 Stop |
| Selenium source (unidentified) | STOP | Investigate + eliminate | Selenium at 187.55 µg/L — source must be found (Brazil nuts? unlisted supplement?) | 🛑 Find + Stop |
Jude has made genuine, sustained metabolic progress over 15 months — the insulin and triglyceride improvements are measurable and real. The priority issue is not declining health, it's an unreviewed supplement protocol: two overlapping B-complex products are causing B6 and B2 toxicity that is almost certainly driving the free testosterone decline. Stopping both B-complex products is the single most impactful action right now. The D3 story is actually positive — 27.53 ng/mL is a solid unsupplemented natural baseline, and the DV 60K weekly loading protocol just started will push levels to 50–80 ng/mL within 10 weeks. The inflammatory spike is most likely infection-related and should resolve on retest. Identify the selenium source, add isolated benfotiamine and magnesium glycinate, and the next panel at 90 days should show material improvement across free testosterone, B vitamins, D3, inflammatory markers, and Apo A1 simultaneously.